CagriSema

At a glance

Overview

CagriSema is a combination of two active peptides, rather than a new generic name for semaglutide alone. Cagrilintide adds amylin-related appetite signaling to semaglutide’s GLP-1 effects. The REDEFINE program has studied adults with obesity or overweight, including separate populations with and without type 2 diabetes. The sponsor filed a U.S. application in December 2025 and reported continued review during 2026. As of this review date, the combination is not treated as an approved medicine. Manufacturing or mixing the components outside the studied product does not reproduce the trial evidence automatically.

Supporting sources [1] [2] [3] [4]

How it works

Semaglutide activates GLP-1 receptors and influences appetite, glucose-dependent insulin secretion and gastric emptying. Cagrilintide provides prolonged amylin-related receptor activity affecting satiation. Combining the pathways aims to improve weight reduction beyond either component alone, but also combines pharmacologic burdens, especially gastrointestinal effects. The net result must be demonstrated in clinical trials rather than inferred solely from having two mechanisms.

Supporting sources [1] [2] [3] [4]

Which populations were studied

REDEFINE 1 enrolled adults with obesity or qualifying overweight without diabetes. REDEFINE 2 addressed overweight or obesity with type 2 diabetes. Different baseline physiology and treatments mean that results from one population do not predict identical effects in the other.

Supporting sources [1] [2]

Phase 3 efficacy

REDEFINE 1 randomized 3,417 participants. In the treatment-policy analysis, mean weight change at sixty-eight weeks was −20.4% with the combination and −3.0% with placebo. The trial also included individual-component groups, allowing direct evaluation within that study.

Supporting sources [1]

Gastrointestinal burden

Nausea, vomiting, diarrhea, constipation and abdominal pain were frequent in REDEFINE 1, usually transient and mild to moderate. A mean weight-loss benefit must be considered alongside discontinuation, tolerability and the practical ability to continue therapy.

Supporting sources [1]

Head-to-head evidence

The sponsor reported that REDEFINE 4 did not meet its primary noninferiority objective against tirzepatide. This directly comparative finding matters more than ranking drugs from unrelated trials with different durations and statistical analyses.

Supporting sources [3]

Semaglutide approval does not approve the combination

The sponsor’s 2026 filing states that the combination’s U.S. application was submitted in December 2025. Existing semaglutide approvals do not extend automatically to cagrilintide or CagriSema, and a pending application is not a final marketing authorization.

Supporting sources [3]

Common questions

Does Wegovy approval also approve CagriSema? No. Adding cagrilintide produces a different investigational combination that needs its own regulatory assessment.

Did every comparison favor CagriSema? No. Although placebo-controlled phase 3 studies demonstrated substantial weight loss, the sponsor reported that REDEFINE 4 did not meet its primary noninferiority comparison with tirzepatide. That distinction belongs alongside the positive results.

Supporting sources [1] [2] [3]